Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.62 |
| ▸ | FHIT | P49789 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245696 | 0.91 | CYP11B1 (0.59) | ALDH1A1HPGDHSD17B10CYP11B1CYP19A1 | |
| SCHEMBL14090253 | 0.87 | CYP19A1 (0.59) | ALDH1A1HPGDHSD17B10CYP11B1CYP19A1 | |
| SCHEMBL2617479 | 0.86 | KDM4E (0.71) | ALDH1A1HPGDHSD17B10LMNAMMP2 | |
| SCHEMBL19970775 | 0.85 | FHIT (0.80) | ALDH1A1HPGDHSD17B10CYP11B1FHIT | |
| SCHEMBL20982471 | 0.85 | MMP2 (0.78) | ALDH1A1HPGDLMNAMMP2MMP9 | |
| SCHEMBL18229646 | 0.84 | HDAC6 (0.72) | ALDH1A1HPGDHSD17B10CYP11B1FHIT | |
| SCHEMBL14115930 | 0.83 | MMP2 (0.65) | ALDH1A1HPGDLMNAMMP2MMP9 | |
| SCHEMBL4033970 | 0.83 | NEK1 (0.52) | ALDH1A1HPGDHSD17B10CYP11B1CYP19A1 | |
| SCHEMBL26755411 | 0.81 | HPSE (0.64) | ALDH1A1HPGDHSD17B10CYP11B1FHIT | |
| SCHEMBL19763371 | 0.80 | CHEK2 (0.72) | ALDH1A1HPGDLMNAMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| WO-2018050771-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-22 | — | — | WO | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | ALDH1A1 1822/4885HPGD 3309/4885HSD17B10 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.